Olivia Heffernan

A Randomized Trial Evaluating Patient Experience and Preference Between Octreotide Long-Acting Release and Lanreotide for Treatment of Well-Differentiated Neuroendocrine Tumors

L. Saltz, N. Raj, M. Capanu, 2022, JCO oncology practice.